ACRO Issues Comments to CMS on Proposed Rules

By ACRO
Press Release
Article

As noted in the letters, "ACRO’s comments seek to ensure ongoing access to high-quality, state-of-the-art radiation oncology services."

ACRO submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule for the CY 2026 Physician Fee Schedule (CMS-1832-P), as well as the CY 2026 Hospital Outpatient Prospective Payment System Proposed Rule (CMS-1834-P).

ACRO submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule for the CY 2026 Physician Fee Schedule (CMS-1832-P), as well as the CY 2026 Hospital Outpatient Prospective Payment System Proposed Rule (CMS-1834-P).

ACRO has submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule for the CY 2026 Physician Fee Schedule (CMS-1832-P), as well as the CY 2026 Hospital Outpatient Prospective Payment System Proposed Rule (CMS-1834-P).

The first letter (CMS-1832-P) offers comments and recommendations on the following issues:

  • Appropriate APC Placement for Treatment Delivery Codes (77402, 77407, 77412)
  • Use of OPPS data to set PFS rates
  • Updates to the Indirect Practice Expense (PE) Methodology
  • Removal of 77427 from the Telehealth List
  • Undervaluation of conversion factor due to G2211 Assumption
  • Efficiency Adjustment
  • Valuation of Imaging Guidance for Proton Beam Treatment Delivery (CPT codes 77520, 77522, 77523, and 77525)

The second letter (CMS-1834-P) offers comments on:

  • Appropriate APC Placement for Treatment Delivery Codes (77402, 77407, 77412)
  • BgRT

Click here to learn more and review the two letters submitted.

Recent Videos
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content